PMID- 33520343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210202
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 10
IP  - Suppl 3
DP  - 2019 May-Jun
TI  - CAR T-Cell Therapy: Adverse Events and Management.
PG  - 21-28
LID - 10.6004/jadpro.2019.10.4.11 [doi]
AB  - Chimeric antigen receptor (CAR) T-cell therapy is an exciting innovation in the 
      treatment of cancer. However, CAR T-cell therapies have been associated with 
      unique adverse events (AEs), including cytokine release syndrome (CRS) and 
      neurologic events (also known as CAR T-cell-related encephalopathy syndrome 
      [CRES] or, most recently, immune effector cell-associated neurotoxicity syndrome 
      [ICANS]). Cytopenias and infection have also been observed. These AEs are 
      treatable and reversible with appropriate treatment strategies but can become 
      severe if not managed early. Therefore, it is essential for the advanced 
      practitioner caring for patients undergoing these therapies to have a thorough 
      understanding of the associated AEs, in particular their grading and management. 
      Cytokine release syndrome and neurologic events can range in severity from 
      low-grade symptoms that require supportive care only to a high-grade syndrome 
      that can become life-threatening. While several grading and management 
      recommendations have been used in clinical trials, until recently, there were no 
      consistent grading and management guidelines. Here we provide the most recent 
      recommendations, which have the ultimate goal of maintaining the benefits of CAR 
      T-cell therapy, while minimizing life-threatening AEs. Improved understanding and 
      management of AEs associated with CAR T-cell therapy will provide broader access 
      to this innovative and potentially curative technology.
CI  - (c) 2019 Harborside.
FAU - Adkins, Sherry
AU  - Adkins S
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190501
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC7521123
COIS- This manuscript was sponsored by Kite, a Gilead Company. Ms. Adkins has served as 
      a consultant for Kite, a Gilead Company, and Juno Therapeutics.
EDAT- 2019/05/01 00:00
MHDA- 2019/05/01 00:01
PMCR- 2019/05/01
CRDT- 2021/02/01 05:58
PHST- 2021/02/01 05:58 [entrez]
PHST- 2019/05/01 00:00 [pubmed]
PHST- 2019/05/01 00:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - 2019.10.4.11 [pii]
AID - 10.6004/jadpro.2019.10.4.11 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2019 May-Jun;10(Suppl 3):21-28. doi: 
      10.6004/jadpro.2019.10.4.11. Epub 2019 May 1.